A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Quotient Sciences.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
16actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-11 | actual | When the study began enrolling |
| Primary completion | 2026-05-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-26 | actual | The whole study's end, after follow-up |
| First posted | 2026-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: [14C]AZD4144 Solution for Infusion — also filed as AZD4144
- Drug: [14C]AZD4144 Oral Solution — also filed as AZD4144
Primary outcomes
what the primary-completion date above is the date OFAmount of AZD4144 excreted (Ae)
measured Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (Fe)
measured Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Cumulative amount of AZD4144 excreted (CumAe)
measured Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Cumulative amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (CumFe)
measured Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Area under the curve (AUC) of circulating plasma total radioactivity (TR) accounting for 10% or more of the dose
measured Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
80% or more of the radioactivity recovered in excreta
measured Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed